Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Impact of anti-CGRP monoclonal antibodies on central sensitization level in migraine patients
https://doi.org/10.33667/2078-5631-2023-33-8-12
Abstract
Background. Central sensitization (CS) is the mechanism underlying chronic migraine and other conditions combined into a group of central sensitivity syndromes. The most reliable method for assessing the severity of CS is Central Sensitization Inventory (CSI).
Aim. The aim of our study is the evaluation of anti-CGRP monoclonal antibodies (erenumab, fremanezumab) effect on the central sensitization level in migraine patients.
Material and methods. We recruited 90 patients over 18 years old diagnosed with episodic migraine (EM) and chronic migraine (CM) according to the International Classification of Headache Disorders, 3rd edition. All patients were from November 2020 to March 2022. Demographic data, history of migraine and previous migraine treatment were collected for each patient. All patients filled out CSI. Dynamics was followed up monthly with headache diaries.
Results. After six months of treatment the level of CS in the CM group significantly decreased from the initial level of 41 (32.0, 50.5) to 36 (25.0, 39.0), which corresponds to the absence of clinically significant CS, p = 0.02*. The analysis of points of the CSI after 3 months of treatment shows a significant decrease in the prevalence of pain syndromes, cognitive impairment, asthenic disorders, hypersensitivity and affective disorders.
Conclusions. The use of erenumab and fremanezumab is advisable in patients with migraine and comorbid conditions based on the CS mechanism.
About the Authors
A. V. Berdnikova
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Berdnikova Anna V., assistant at Dept of Neurology of Institute of Professional Education
Moscow
N. B. Kadymova
Cephalgolog Co. – Headache and Vegetative Disorders Clinic n. a. academician Alexander Vein – Clinical Base of I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Kadymova Natalya B., PhD Med, neurologist
Moscow
N. V. Latysheva
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Latysheva Nina V., DM Sci (habil.), associate professor, professor at Dept of Neurology of Institute of Professional Education
Moscow
E. G. Filatova
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Filatova Elena G., DM Sci (habil.), professor, professor at Dept of Neurology of Institute of Professional Education
Moscow
References
1. Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain. 2009; 10 (9): 895–926. https://doi.org/10.1016/j.jpain.2009.06.012
2. Yunus MB. Fibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. 2007; 36: 339–356. https://doi.org/10.1016/j.semarthrit.2006.12.009
3. Mayer TG, Neblett R, Cohen H, et al. The development and psychometric validation of the central sensitization inventory. Pain Pract. 2012; 12 (4): 276–285. https://doi.org/10.1111/j.1533–2500.2011.00493.x
4. Andreou AP, Fuccaro M, Lambru G. The role of erenumab in the treatment of migraine. Ther Adv Neurol Disord. 2020; 13: 1756286420927119. https://doi.org/10.1177/1756286420927119
5. Urits I, Clark G, An D, et al. An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain Ther. 2020; 9: 195–215. https://doi.org/10.1007/s40122–020–00159–3
6. Zenkevich A. S., Filatova E. G., Latysheva N. V. Migraine and comorbid pain. Medical Council. 2016 (8): 106–115. (In Russ.) https://doi.org/10.21518/2079–701x‑2016–8–106–115
7. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders (3rd edition). Cephalalgia. 2018; 38: 1–211. https://doi.org/10.1177/0333102417738202
8. Tabeeva G. R., Osipova V. V., Filatova E. G., et al. Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (1): 4–13. (In Russ.) https://doi.org/10.14412/2074–2711–2022–1–4–13
9. Esin OR, Gorobets EA, Khayrullin IKh, et al. R. Central Sensitization Inventory – a Russian version. Journal of Neurology and Psychiatry n. a. S. S. Korsakov. 2020; 120 (6): 51–56. (In Russ.) https://doi.org/10.17116/jnevro202012006151
10. Lipton RB, Burstein R, Buse DC, et al. Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. Cephalalgia. 2021; 41 (11–12): 1152–1160. https://doi.org/10.1177/0333102421101030
11. Noor-Mohammadi E, Ligon CO, Mackenzie K, et al. A Monoclonal Anti-Calcitonin Gene-Related Peptide Antibody Decreases Stress-Induced Colonic Hypersensitivity. J Pharmacol Exp Ther. 2021; 379 (3): 270–279. https://doi.org/10.1124/jpet.121.000731
12. Berdnikova A. V., Kadymova N. V., Latysheva N. V., Naprienko M. V., Filatova E. G. Real-world efficacy and safety of Erenumab: A prospective study of 80 patients in a specialized headache center. Russian Neurological Journal. 2022; 27 (1): 43–50. (In Russ.) https://doi.org/10.30629/2658–7947–2022–27–1–43–50
13. Suzuki K, Haruyama Y, Kobashi G, et al. Central Sensitization in Neurological, Psychiatric, and Pain Disorders: A Multicenter Case-Controlled Study. Pain Res Manag. 2021; 6656917. https://doi.org/10.1155/2021/6656917
14. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=35edaaeb-7419-493f-827d-425007e01fb1
Review
For citations:
Berdnikova A.V., Kadymova N.B., Latysheva N.V., Filatova E.G. Impact of anti-CGRP monoclonal antibodies on central sensitization level in migraine patients. Medical alphabet. 2023;(33):6-12. (In Russ.) https://doi.org/10.33667/2078-5631-2023-33-8-12
Views:
308
Email this article 